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Abstract
Acinetobacter baumannii has emerged as an important cause of
community-acquired infection. To characterize the microbiologi-
cal and genotypic features of community-associated Acinetobacter
baumannii, 32 isolates associated with community-acquired pneu-
monia were collected. These isolates were diverse in resistance
patterns and had multiple clonal origins. blaOXA-23 was the main
acquired oxacillinases-encoding gene detected.
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Acinetobacter baumannii is responsible for a variety of nosoco-
mial infections [1] and has also been found to be an
important cause of community-acquired infection [2]. Com-
munity-acquired pneumonia due to A. baumannii (CAP-AB) is
characterized by a fulminate course with high mortality rates,
which was significantly different from hospital-acquired pneu-
monia due to A. baumannii (HAP-AB) [2–4]. Recent studies
found that HAP-AB and CAP-AB isolates were significantly
different in antimicrobial susceptibility profiles [2,4,5]. The
aim of the study was to characterize the microbiological and
genotypic features of A. baumannii isolates associated with
CAP.
Thirty-two adult patients with CAP were studied. Pneu-
monia was defined according to the Infectious Diseases
Society of America (IDSA) guidelines [6]. CAP was consid-
ered if pneumonia was acquired outside a hospital and the
interval between symptom onset and previous discharge was
>30 days. Community-associated A. baumannii was defined as
isolates grown from sputum and/or blood from CAP patients
and collected within 48 h after admission. All sputum speci-
mens were in good quality for culture as checked by micros-
copy. Species identifications were initially performed using
the MicroScan Walkaway 96 SI automated system (Siemens
Healthcare Diagnostic, Deerfield, IL, USA). The identification
of A. baumannii was confirmed partially by sequencing the
recA gene as described previously [7,8]. Susceptibilities of the
isolates to antimicrobial agents including piperacillin-tazobac-
tam, ceftazidime, cefepime, aztreonam, amikacin, imipenem,
meropenem, ciprofloxacin, sulbactam, polymyxin and minocy-
cline, were tested using the agar dilution method and were
interpreted following the recommendations of the Clinical
and Laboratory Standards Institute (CLSI) [9]. Multiplex PCR
was used to detect the presence of carbapenemase-encoding
genes, including the oxacillinase genes(blaOXA-23, blaOXA-24,
blaOXA-58 and blaOXA-51) and the metallo-b-lactamases (MBL)
genes (blaGIM-1, blaSIM-1, blaSPM-1, blaIMP and blaVIM) as
described previously [10,11]. In addition, PCR was also used
to detect blaOXA-143, blaNDM-1 [12] and whether ISAba1 was
located upstream of blaOXA-51-like or blaOXA-23 genes. All
clinical isolates were typed using pulsed-field gel electropho-
resis (PFGE) analysis. PFGE was performed on a CHEF-DRII
system (Bio-Rad, Hercules, California, USA) for 20 h at
14C, using a linear ramped pulse time of 5–20 s at 200 V.
DNA fingerprints were interpreted as recommended by
Tenover et al. [13]. Univariate analysis was conducted using
Pearson’s chi-square test for categorical variables and the
Mann–Whitney U-test for continuous variables. A p value of
<0.05 was considered significant.
Of the CAPs associated with A. baumannii, 27 (84.4%) were
patients with underlying chronic obstructive pulmonary dis-
ease. Susceptibility testing showed that 15 isolates were mul-
tidrug-resistant A. baumannii (MDR-AB) [14] and 17 isolates
were non-MDR-AB (Table 1). A. baumannii was considered as
MDR if it was resistant to three or more classes of antimicro-
bial agents. The clinical characteristics and predisposing fac-
tors of patients from whom MDR-AB and non-MDR-AB
were isolated are shown in Table 2. The mortality of MDR-
AB was significantly higher than that of non-MDR-AB. Histo-
ries of mechanical ventilation and previous antibiotic use
were significantly more frequent in patients with MDR-AB
than in those with non-MDR-AB. The isolates all contained a
blaOXA-51-like gene but no ISAbal was detected upstream;
blaOXA-23 with ISAba1 detected upstream was only found in
MDR isolates. MBL and other blaOXA genes were not
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detected in any isolates (the results of PCR are shown in
Table 3). PFGE showed that these isolates could be grouped
into 11 clonal patterns, distinct from the mainly clonal dis-
semination hospital isolates [15,16]. Isolates with the clonal
pattern were diverse in resistance profiles including MDR and
non-MDR and those from patients with a hospitalization his-
tory, third-generation cephalosporin use and mechanical ven-
tilation were more frequently MDR-AB isolates.
According to studies published previously [2,4,5], resis-
tance rates of A. baumannii in the community and their MIC
to most antimicrobial agents were lower than those in hospi-
tal. However, in this study over 30% of A. baumannii isolates
were resistant to most commonly-used antimicrobial agents
and the resistant rates of imipenem and meropenem were
18.75% and 9.375%, respectively. Of note, the resistance
phenotypes of the isolates with the same PFGE pattern were
different, which appear to be related to predisposing factors
of host patients. Mechanical ventilation, hospitalization his-
tory and third-generation cephalosporin or fluoroquinolone
use appeared to be associated with resistance level and resis-
tance genes detected in isolates with the same PFGE pattern.
We hypothesize that chronic obstructive pulmonary disease
may result in repeated hospitalizations during which patients
are more likely to become colonized with A. baumannii and
probably develop invasive diseases sometime after discharge,
even after 30 days post-discharge. The different resistance
profiles of isolates with the same clonal origin but different
hospitalization history seemed to suggest that the resistant
strains in the community may come from the hospital envi-
ronment and the selective pressure of third-generation ceph-
alosporins affected the antimicrobial resistance of
A. baumannii. Nonetheless, further studies are warranted as
only a small number of isolates was included here.
Several previous studies have demonstrated that acquired
resistance to carbapenems in A. baumannii is mainly mediated
by class D b-lactamases and MBLs [1]. blaOXA-23 and blaOXA-






rate (%)Range 50% 90%
Sulbactam 0.03–16 0.25 16 )*
Meropenem 0.03–32 0.03 8 87.5
Imipenem 0.03–16 0.0625 16 65.625
Cefepime 0.03–128 1 16 59.375
Ceftazidime 0.03–128 2 64 50
Aztreonam 0.03–512 8 64 21.875
Piperacillin-tazobactam 0.03–128 8 8 50
Minocycline 0.03–1 0.03 0.25 100
Polymyxins 0.03–0.03 0.03 0.03 100
Ofloxacin 0.03–128 0.03 64 46.875
Amikacin 0.03–512 0.0625 512 53.125
*The breakpoints were not defined by the Clinical and Laboratory Standards
Institute.
TABLE 2. Clinical characteristics and predisposing factors of
patients from whom Acinetobacter baumannii were isolated
Variable MDR (n = 15)
non-MDR
(n = 17)
Male gender 11 (73.3%) 12 (70.6%)
Age (years), mean ± SD 68.2 ± 13.1 59 ± 13.5
Hospitalization history, no. (%) 13 (86.7%) 7 (41.2%)*
Co-morbid disease, no. (%)
Chronic obstructive
pulmonary disease
15 (100%) 12 (70.6%)
Other pulmonary disease 5 (38.5%) 7 (41.2%)
Malignancy 3 (20.0%) 3 (17.6%)
Medication, no. (%)
Immunosuppressive therapy 8 (53.3%)
Mechanical ventilation 10 (66.7%) 2 (11.8%)*
Previous use of antibiotics
within 2 months
12 (80.0%) 7 (41.2%)*
Cephalosporins
First-generation 0 1 (5.9%)
Second-generation 3 (33.3%) 1 (5.9%)
Third-generation 8 (53.3%) 4 (23.5%)*
Fluoroquinolones 7 (46.7%) 3 (17.6%)*
Aminoglycosides 4 (26.7%) 5 (29.4%)
Carbapenems 3 (20.0%) 0
Mortality 7 (46.7%) 2 (11.8%)*
*p <0.05.
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51-like genes were detected in this study while other OXA-
type carbapenemase and MBLs were not detected. blaOXA-51-
like genes are widely distributed in A. baumannii, including
carbapenem-susceptible isolates [17]. blaOXA-23 contributes
to carbapenem resistance in A. baumannii globally [1] and
was recently detected in environmental A. baumannii resistant
to carbapenem [18]. In these isolates from the community,
the data also indicated that the blaOXA-23 gene was consis-
tently associated with isolates resistant to, or at least with
reduced susceptibility to, carbapenems (MIC2-32 mg/L com-
pared with MIC0-8 mg/L). However, blaOXA-23 was not only
found in carbapenem-resistant isolates but was also present
in imipenem-intermediate or meropenem-susceptible isolates,
as exemplified by Wang et al. [19]. The genetic backgrounds
in the process of acquiring blaOXA-23 are diverse [20] and
another non-enzymic mechanism could also mediate carbape-
nem resistance [1].
In conclusion, our results suggest that the epidemiology of
A. baumannii from the community is of multiclonal origins,
different from those in hospital settings. The resistant pheno-
types of isolates from the community are diverse. Mechanical
ventilation and third-generation cephalosporin use seem to
be the risk factors for acquiring MDR-AB. blaOXA-23 is the
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